AxoGen, Inc. $AXGN Shares Sold by First Eagle Investment Management LLC

AxoGen logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • First Eagle Investment Management cut its AxoGen stake by 53.3% in the third quarter, selling 363,452 shares and ending the period with 318,702 shares worth about $13.36 million.
  • Institutional investors showed mixed activity: Russell Investments increased its holdings by 163.7%, while institutional investors and hedge funds collectively owned 80.29% of AxoGen stock.
  • AxoGen reported quarterly EPS of $0.21, beating the $0.13 analyst consensus, and revenue of $75.83 million versus estimates of $73.45 million. Analysts’ average rating was “Moderate Buy,” with an average price target of $57.92.
  • Five stocks to consider instead of AxoGen.

First Eagle Investment Management LLC trimmed its holdings in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 53.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 318,702 shares of the medical equipment provider's stock after selling 363,452 shares during the period. First Eagle Investment Management LLC owned approximately 0.53% of AxoGen worth $13,360,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. White Pine Capital LLC acquired a new position in shares of AxoGen during the 3rd quarter worth approximately $1,812,000. Russell Investments Group Ltd. boosted its holdings in shares of AxoGen by 163.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 334,902 shares of the medical equipment provider's stock valued at $14,039,000 after buying an additional 207,916 shares during the last quarter. Lisanti Capital Growth LLC boosted its holdings in shares of AxoGen by 21.9% in the 3rd quarter. Lisanti Capital Growth LLC now owns 110,420 shares of the medical equipment provider's stock valued at $4,629,000 after buying an additional 19,855 shares during the last quarter. Advisor Resource Council boosted its holdings in shares of AxoGen by 6.8% in the 3rd quarter. Advisor Resource Council now owns 8,749 shares of the medical equipment provider's stock valued at $367,000 after buying an additional 556 shares during the last quarter. Finally, Calamos Advisors LLC grew its stake in shares of AxoGen by 15.8% in the third quarter. Calamos Advisors LLC now owns 110,210 shares of the medical equipment provider's stock valued at $4,620,000 after buying an additional 15,064 shares in the last quarter. 80.29% of the stock is currently owned by institutional investors and hedge funds.

AxoGen Stock Performance

AXGN opened at $56.95 on Thursday. The company has a quick ratio of 10.67, a current ratio of 12.02 and a debt-to-equity ratio of 0.04. AxoGen, Inc. has a 12-month low of $23.61 and a 12-month high of $59.72. The business has a 50 day moving average of $43.78 and a 200-day moving average of $40.76. The stock has a market cap of $3.40 billion, a price-to-earnings ratio of -87.62 and a beta of 1.21.

AxoGen (NASDAQ:AXGN - Get Free Report) last posted its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 earnings per share for the quarter, topping analysts' consensus estimates of $0.13 by $0.08. AxoGen had a negative return on equity of 5.35% and a negative net margin of 11.96%. The business had revenue of $75.83 million for the quarter, compared to analyst estimates of $73.45 million. On average, equities research analysts expect that AxoGen, Inc. will post -0.36 earnings per share for the current year.

Analyst Ratings Changes

AXGN has been the topic of a number of recent analyst reports. Wells Fargo & Company boosted their target price on shares of AxoGen from $48.00 to $56.00 and gave the stock an "overweight" rating in a report on Thursday, October 29th. Raymond James Financial reiterated an "outperform" rating and issued a $57.00 price target on shares of AxoGen in a research note on Thursday, October 29th. Weiss Ratings reissued a "sell (d-)" rating on shares of AxoGen in a research report on Wednesday, August 26th. HC Wainwright boosted their price objective on shares of AxoGen from $53.00 to $56.00 and gave the stock a "buy" rating in a research note on Thursday, October 29th. Finally, Canaccord Genuity Group boosted their price objective on shares of AxoGen from $55.00 to $60.00 and gave the stock a "buy" rating in a research note on Thursday, October 29th. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $57.92.

Read Our Latest Stock Analysis on AXGN

Insider Buying and Selling

In other AxoGen news, Director Joseph Tyndall sold 3,500 shares of the company's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $49.70, for a total value of $173,950.00. Following the transaction, the director directly owned 10,650 shares in the company, valued at $529,305. The trade was a 24.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.44% of the stock is currently owned by company insiders.

About AxoGen

(Free Report)

AxoGen, Inc. is a medical technology company focused on repairing peripheral nerve injuries—damage to nerves outside the brain and spinal cord. Its products are used by surgeons in procedures intended to restore nerve function and sensation. The company's offerings include Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves, and Axoguard products designed to protect, connect or cap nerves during repair. Axogen also provides education and support for healthcare professionals who use its nerve-repair solutions.

Featured Stories

Institutional Ownership by Quarter for AxoGen (NASDAQ:AXGN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AxoGen Right Now?

Before you consider AxoGen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AxoGen wasn't on the list.

While AxoGen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines